Evidence map›Paper›PMID 24357133›Full record

ArticleDrugs & aging2014

Medication for Alzheimer's disease and associated fall hazard: a retrospective cohort study from the Alzheimer's Disease Neuroimaging Initiative.

Noam U Epstein, Rong Guo, Martin R Farlow, Jaswinder P Singh, Morris Fisher

Abstract read
In one paragraph

Article in Drugs & aging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Falls and Alzheimer Disease.Advances in geriatric medicine and research · 2024
    Article
  8. Review
  9. Observational
  10. The Efficacy of Fall Hazards Identification on Fall Outcomes: A Systematic Review With Meta-analysis.Archives of rehabilitation research and clinical translation · 2020
    Review
  11. Falls Risk and Alzheimer Disease: A Patient Guide.Archives of physical medicine and rehabilitation · 2020
    Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Noam U EpsteinDepartment of Neurology, Hines VA Medical Center, 5000 South 5th Avenue, Hines, IL, 60141, USA, nue2you@gmail.com.
Rong Guo
Martin R Farlow
Jaswinder P Singh
Morris Fisher

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
UC Davis Alzheimer's Disease Core CenterP30AG010129 · NIA · UNIVERSITY OF CALIFORNIA DAVIS · PI MEYER, OANH L · 1991 to 2020
$28.3M
"MR Morphometrics and Cognitive Decline Rate in Large-Scale Aging Studies"K01AG030514 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CARMICHAEL, OWEN T. · 2008 to 2012
$495k
CIHRNIA NIH HHS K01 AG030514NIA NIH HHS P30 AG010129NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

backgroundFalls are common in the elderly, especially in those with cognitive impairment. The elderly are often treated with several medications, which may have both beneficial and deleterious effects. The use and type of medication in Alzheimer's disease (AD) patients and association with falls is limited.

objectiveWe examined the association between falls and medication use in the Alzheimer's Disease Neuroimaging Initiative (ADNI).

methodsDiagnosis, demographics, medication use, apolipoprotein E4 allele status and functional activity level at baseline were gathered for 810 participants enrolled in the ADNI, including healthy controls and subjects with mild cognitive impairment or Alzheimer's. Reports detailing adverse event falls were tabulated. Baseline characteristics were compared between subjects with and without one or more falls. Cox proportional hazards models were conducted to evaluate the association between subject characteristics and hazard of the first fall.

resultsAge (p < 0.0001), Functional Activities Questionnaire (p = 0.035), Beers List (p = 0.0477) and medications for treating cognitive symptoms of Alzheimer's (p = 0.0019) were associated with hazard of fall in the univariate model. In the final multivariate model, after adjusting for covariates, Alzheimer's medication use (p = 0.0005) was associated with hazard of fall. Medication was changed by the clinician after an adverse fall event in 9% of the falls. About 7% of the falls were reported as serious adverse events and 6% were reported to be severe.

conclusionWe found a significant association between the use of symptomatic medication treating cognitive symptoms in AD and hazard of fall after adjusting for age and Beers List medication use. Additional pharmacovigilance of the association between falls and Alzheimer's medication use is warranted.

Indexed as

Accidental FallsAgedAged, 80 and overAllelesAlzheimer DiseaseApolipoprotein E4Case-Control StudiesCholinesterase InhibitorsCognition DisordersCognitive DysfunctionHumansMemantineMultivariate AnalysisNeuroimagingProportional Hazards ModelsRetrospective StudiesApolipoprotein E4Cholinesterase InhibitorsMemantine

Identifiers

PMID24357133
PMCPMC5469288

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.